利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1 条记录 (耗时 0.014 秒)

    COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS
    1.
    发明公开
    COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS 审中-公开
    结合治疗EGFR激酶HEMMBER和活跃，表皮生长因子受体激酶抑制剂的作用，肿瘤细胞致敏

    公开(公告)号：EP1996193A2

    公开(公告)日：2008-12-03

    申请号：EP07753017.8

    申请日：2007-03-13

    申请人： OSI Pharmaceuticals, Inc.

    发明人： BUCK, Elizabeth, A. ,  GRIFFIN, Graeme ,  BARR, Sharon, M.

    IPC分类号： A61K31/436 ,  A61K31/498 ,  A61K45/06 ,  A61P35/00

    CPC分类号： A61K45/06 ,  A61K31/436 ,  A61K31/498 ,  A61K2300/00

    摘要： The present invention provides a method for manufacturing a medicament intended for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in combination with an EGFR kinase inhibitor, characterized in that an mTOR inhibitor is used, and wherein the inhibitors are intended for administration either simultaneously or sequentially, and with or without administration of additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for manufacturing a medicament intended for treating tumors or tumor metastases in a patient in combination of an EGFR kinase inhibitor, characterized in that an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases is used, and wherein the inhibitors are intended for administration either simultaneously or sequentially, and with or without administration of additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA®).